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INTRODUCTION
Ziprasidone is a novel atypical antipsychotic with unique
pharmacological profile and was approved by FDA in Feb.
2001 for the treatment of psychotic disorders. It is used
widely because of better side effect profile. In recent years,
concern about reports of sudden unexpected death occurring
in psychiatric patients being treated with atypical
antipsychotics has been raised (Haddad et al, 2002). The
possibility of a causal link has been a controversial area
and need further research to quantify the risk of sudden
death with atypical antipsychotics. Here, we are presenting
a case report of a psychotic female patient who was taking
Ziprasidone for one month and she died suddenly in the
psychiatric ward.
CASE REPORT
Mrs. S.  a 44 years old woman suffering from schizophrenia
for last 2 years was referred to psychiatry from medical
emergency. She was admitted in the Psychiatry ward with
complaints of talking irrelevantly , oddities of behaviour , poor
self-care, poor socialization and suicidal ideas. Mental
examination showed somatic delusions, blunt affect and
poverty of content of speech. Patient had no previous history
of cardiovascular disorders (Hypertension,arrythmias,other
medical illnesses or neurological disorders). Patient was
receiving 120 mg/day of Ziprasidone for last one month
and had also received three modified ECT after pre-
anaesthetic check-up, two months before from a private
psychiatrist. There was no ECT related side effects and
patient did not show any improvement with ECT . After
admission in psychiatry ward, all routine investigations
(Haemogram, Serum electrolytes, RFT & TFT) were
within normal limits.
The dose of Ziprasidone was increased to 160 mg/day and
within 4 days, patient showed improvement in
communication, oral intake, self care and became
cooperative. On 5th day , she was asked to have a stroll
within the ward. After 10-15 steps, she suddenly fell down
on the ground in front of the nursing station and turned
unconscious with great difficulty in respiration.  On
examination, patient was unresponsive and had fast, feeble,
low volume pulse which otherwise appeared regular and
blood pressure was unrecordable. All emergency
resuscitative measures were tried by the anesthetist and
the physician, but despite all resuscitative interventions
patient could not be revived.  Apparently, patient did not
have underlying physical or neurological disorder leading
to sudden death. However, such a conclusion was dif ficult
to be drawn in the absence of autopsy findings. It is possible
that the sudden death might have been caused by
Ziprasidone leading to ventricular tachyarrhythmias after
the dose was increased to 160 mg/day . It may be
hypothesized that patient might had been at risk because of
some underlying sub-clinical cardiac pathology , which was
probably missed and sudden death was the result of an
adverse cardiovascular event viz. tachyarrhythmia   induced
by Ziprasidone. Even though sudden death  with Risperidone
(Ravin et al,1997) and serious cardiac problems with
clozapine (Modai et al,2002) has been reported, this is the
first such report of Ziprasidone associated sudden cardiac
death. All antipsychotic drugs have the potential for serious
adverse events. Balancing these risks with the positive
effects of antipsychotic drugs poses a challenge for
psychiatry (Glassman et al, 2001). Ziprasidone does prolong
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the QTc interval but more evidence is    required to establish
that it can lead to torsade de pointes or sudden death (T aylor,
2003).
It is being suggested that more research is needed to prove
if Ziprasidone is entirely safe and meanwhile the base line
ECG and cardiologist opinions may be sought in patients
who are above 40 years of age. The dose of Ziprasidone
may be titrated more slowly . Also the coprescription of
ziprasidone with other drugs that prolong the QT interval
should be avoided (T aylor,2003). The mental health
professional should be made aware of cardiac risk
associated with Ziprasidone, till it is concluded that it is
safe.
Limitation
Base line ECG was not done to comment on the  pre-
treatment status of cardiac functioning.
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